Advertise on podcast: Science Will Win

Cancer research is moving faster than ever—but too many patients never feel the impact of that progress. Artificial Intelligence (AI) is emerging as one tool that could help change that.  In the Season 6 finale of Science Will Win, Dr. Raven Baxter follows the human journey behind AI in oncology—from the moment of diagnosis to the real‑world barriers that determine access to care.  Along the way, we explore how thoughtfully designed artificial intelligence is reshaping trial design, enrollment, eligibility, and access—helping patients regain agency and bridging the gap between scientific breakthroughs and real‑world cancer care. As the season concludes, one thing is clear: progress matters most when it reaches the people who need it. Featured guests: – Dr. Lionel Kankeu Fonkoua, Medical Oncologist and Translational Researcher, Mayo Clinic – Jeff Legos, Chief Oncology Officer, Pfizer – Dr. Ravi Parikh, Medical Oncologist; Director, Human‑Algorithm Collaboration Lab – Maya R. Said, Founder and CEO, Outcomes4Me Dive into the episode here: 00:00 – Past episodes introduce us to an emerging tech advancement 04:16 – What is a clinical trial? 07:35 – AI accelerating the pace of oncology 12:42 – Clinical trials and AI: How can it help? 16:17 – A gap between innovation and patient access 19:16 – Maya's story 23:47 – Clinical trials for AI tools  27:54 – Conclusion: building pathways alongside scientific innovation Check out our YouTube channel (@Pfizer) to watch full interviews between Raven & some of the patients featured. Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time. *The content in this episode is for informational purposes only and does not provide medical advice. Pfizer does not endorse or sponsor third‑party tools referenced. Patients should not use the tools described as a replacement for discussions with a healthcare provider. Patients should consult their healthcare provider regarding medical decisions. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What comes after a cancer diagnosis and treatment? In this episode of Science Will Win, host Dr. Raven Baxter explores one of the most important, and often overlooked, chapters for cancer patients: survivorship. As five-year survival rates climb to 70%, more people than ever are living with and beyond cancer. But longer survival brings its own complex challenges, and our care systems are still catching up. You'll hear from experts and advocates working at the intersection of medicine, policy, and community. We’ll discuss what it really takes to support people through this transition — when the clinical benchmarks have passed and it’s time to go back to “normal life”. From patient care plans and workplace disclosure to mental health, this episode makes one thing clear: survivorship demands dignity, support, and a whole new kind of care. Featured guests: – Tina Deignan, Commercial President, Pfizer Oncology – Shelley Fuld Nasso, CEO, Cancer Nation – Rebecca Nellis, Executive Director, Cancer and Careers – Bob Riter, Breast Cancer Patient & Advocate Dive into the episode here: 00:00 – The ongoing battle with cancer 03:43 – Rethinking survivorship 05:32 – The five-year survival myth 07:00 – The history of the term "survivor" 09:36 – Bob’s journey with breast cancer 11:38 – Lost in transition and survivorship care plans 14:25 – The intersection of cancer and work 18:49 – Rethinking how work gets done 20:00 – Disclosure and improving company culture 20:59 – The swivel technique 23:19 – Controlling your narrative 25:11 – Standardizing long-term survivorship care through policy 27:08 – Lack of access to care leads to disparities in survival rates 29:48 – Bob's second journey with cancer  32:21 – Takeaways and peek into our final episode Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Bob Riter on his cancer journey. Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What women carry through cancer is more than a diagnosis.  In our third episode of this miniseries, Dr. Raven Baxter explores how generations of women turned silence into advocacy and fear into progress, reshaping the perceptions and discussions around cancer over time. Through history, science, and a powerful story from Katrina M. Johnson — a woman who has lived through multiple breast cancer diagnoses and now advocates for others — the episode highlights how women continue to drive change in how cancer is understood, treated, and lived with. Featured guests: – Dr. Isaac Chan, Physician‑scientist and Assistant Professor, Department of Internal Medicine, University of Texas Southwestern – Kirsten Gardner, Director of Medical Humanities, University of Texas at San Antonio; Author – Katrina M. Johnson, Breast Cancer Patient; Director of Advocacy and Professional Relations, Pfizer Oncology Dive into the episode here: 00:00 – The start of three cancer diagnoses 02:06 – The history of breast cancer awareness campaigns 09:27 – How the mastectomy has changed 12:59 – Evolving research in breast cancer 15:10 – Breast cancer impacting body image and sexuality 19:29 – Emerging therapies to address breast cancer 21:18 – Addressing the BRCA gene today 23:30 – Breast cancer advocacy then and now 26:08 – Katrina's takeaways about her breast cancer story Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Katrina M. Johnson on her breast cancer journey. Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What if the key to treating cancer was hiding in plain sight – written into its DNA? In this episode of Science Will Win, host Dr. Raven Baxter explores one of the most exciting breakthroughs in cancer care today: the discovery of biomarkers. These tiny molecular signals are helping doctors understand what’s really driving an individual person’s cancer – and opening the door to treatments that can dramatically change patient outcomes. You’ll hear powerful stories from people whose cancers were traced back to a specific biomarker, alongside experts who break down what biomarker testing is, how it works, and why it’s transforming the way we think about cancer treatment.    Biomarkers are showing us that when we understand cancer at its molecular level, a disease that once felt like an unsolvable mystery starts to come into focus. Featured guests: – Dr. Ross Camidge, Director of Thoracic Oncology, University of Colorado – Kelly Huffman, Lung Cancer Patient and Retail Account Manager, Pfizer – Karin Tollefson, Chief Oncology Medical Officer, Pfizer Dive into the episode here: 00:00 – An oncologist’s diagnosis introduces the world of biomarker 03:10 – Defining biomarkers and its history 06:24 – Discovery of the first lung cancer biomarker 08:39 – The start Kelly’s lung cancer journey 16:00 – Biomarkers: how do you test for them? 19:11– Discovery of ALK biomarker shift’s Kelly’s story 22:34 – Landscape of targeted therapy and lung cancer today 25:24 – Moving forward with targeted treatments and conclusion Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Kelly Huffman on her lung cancer journey. Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Why are more young adults getting cancer? That's one of the most pressing questions facing the scientific community today. Traditionally thought of as a disease that affects aging populations, recent data shows that cancer diagnoses for people under the age of 50 are increasing. To tackle this problem, it’ll take a global effort. In this episode you’ll hear from patients, oncologists, researchers and health care providers who are coming together to address this issue head on.  Featured guests: – Dr. Marshall Anthony Jr., social scientist and colorectal cancer patient – Dr. Johanna Bendell, Chief Development Officer of Oncology, Pfizer – Dr. Yin Cao, molecular cancer epidemiologist; Cao Lab leader, Washington University – Dr. Beatrice Dionigi, colorectal cancer surgeon; founder & co‑director, Early Onset Colon and Rectal Cancer Project, Columbia Research Cancer Center – Dr. Susan Zhang, Global Development Lead, Pfizer Oncology Dive into the episode here: 00:00 – A patient story reveals an alarming new trend 6:30 – The data behind the rise of early-onset cancer  10:39 – The global search for a cause   14:13 – The unique challenges facing young people with cancer  20:28 – Screening guidelines and what to expect from a colonoscopy   25:17 – The importance of early detection   27:59 – The conclusion of Marshall's cancer journey  30:23 – What's next, and closing thoughts  Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Dr. Marshall Anthony Jr. on his colorectal cancer journey. Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Science Will Win is back for a new season! Dr. Raven Baxter, a molecular biologist also known as Raven the Science Maven, returns as our host to dive into the latest in oncology: The latest challenges, the latest research, the latest treatment approaches, and the latest sources of progress and optimism keeping researchers going. You’ll hear from leading doctors, cutting-edge scientists, insightful historians, and inspiring patients sharing powerful stories of resilience. Plus, for the first time, you can find full length video discussions led by Raven on Pfizer’s YouTube channel. Season 6 of Science Will Win is coming soon—subscribe to stay tuned in!  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In drug discovery and development, every part of the process matters. Scientists learn from every experiment and every observation. In fact, some of the most cutting-edge advancements in medicine are being dreamed up from findings uncovered in the past.   In this episode, co-hosts Dr. Raven Baxter and Dr. Ronald Gamble dive deep into antibody drug conjugates, a groundbreaking modality that uses targeted antibody engineering to deliver potent chemotherapy directly to cancer-causing cells. They explore the complex ADC creation process and learn how ADCs are changing the standard of care for bladder cancer, from someone with a personal relationship to the disease. Featured Guests: – Renee Barron-Gores, Caregiver – Phoenix Ho, Vice President, Oncology Early Clinical Development, Pfizer – Sharsti Sandall, Executive Director, ADC Biology, Oncology Research Unit, Pfizer Dive into the episode here: 1:16 - Old ideas yield new discoveries 3:01 - How do antibody drug conjugates work? 5:07 - The origins of ADCs 8:36 - ADCs allow for more targeted cancer treatment 10:44 - How are ADCs structured? 14:16 - How do scientists find the best ADC combinations? 18:27 - Developing oncology drugs 22:02 - ADCs and bladder cancer 24:28 - A caregiver’s perspective on cancer treatment 38:12 - Science Will Win Season 5 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter and Dr. Ronald Gamble. It’s produced by Acast Creative Studios. Check out our social media platforms to take a deeper look into the labs and stories we discuss during the episodes: Instagram (@pfizerinc), TikTok (@pfizer) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Protein-protein interactions facilitate numerous bodily processes – everything from the basics of how our muscles contract to the more complex ways cancer can spread through the body. So, what if there was a way to alter some of these interactions? Or even create new ones? In this episode, we’re diving into the fascinating field of molecular glues, a revolutionary modality on the precipice of changing the treatment landscape for certain cancers and potentially other diseases and conditions.  Featured Guests: – Joyann Donaldson, Principal Scientist, Synthesis Group Lead, Pfizer – Jennifer LaFontaine, Head of Oncology Medicinal Chemistry, Pfizer – Neal Sach, Research Fellow, Pfizer – Jillian Spangler, Associate Research Fellow, Pfizer Dive into the episode here: 0:50 - A metaphor to explain molecular glues 2:36 - How do molecular glues work in the body? 5:57 - A new frontier for cancer treatment  13:05 - The history behind molecular glues 16:59 - How do scientists design molecular glues? 19:05 - A visit to Pfizer’s La Jolla labs 32:42 - How can molecular glues change the patient experience? 36:42 - Molecular glues beyond cancer treatment Season 5 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter and Dr. Ronald Gamble. It’s produced by Acast Creative Studios. Check out our social media platforms to take a deeper look into the labs and stories we discuss during the episodes: Instagram (@pfizerinc), TikTok (@pfizer) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The next frontier of medicine is focused on highly targeted drug therapies that could expand the possibilities of individualized patient care. Today, scientists are working on a particular type of molecule that could harness multiple capabilities and treat inflammatory and autoimmune diseases in ways never done before.  In this episode, co-hosts Dr. Raven Baxter and Dr. Ronald Gamble explore how the latest advancements in antibody engineering led to multispecific antibodies—powerhouse molecules that can do the jobs of multiple drugs in one. They learn all about what it takes to assemble these antibodies and the impact they could make on patients—with a patient.   Featured Guests: – Emma Guttman, Chair of the Department of Dermatology, Icahn School of Medicine at Mount Sinai – Amanda Lopez, Patient, Texas Ambassador for the National Eczema Association – Laird Bloom, Senior Director of Biomedicine Design, Pfizer – Thomas Wynn, Vice President of Discovery, Inflammation & Immunology, Pfizer Dive into the episode here: 1:12 - A metaphor for multispecific antibodies 4:08 - How do multispecific antibodies work? 10:39 - The history behind multispecific antibodies 16:29 - How are multispecific antibody drugs are made? 22:58 - An eczema expert on the potential of multispecific antibodies 29:30 - Amanda Lopez's eczema story 40:14 - What's next, and closing thoughts Season 5 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter and Dr. Ronald Gamble. It’s produced by Acast Creative Studios. Check out our social media platforms to take a deeper look into the labs and stories we discuss during the episodes: Instagram (@pfizerinc), TikTok (@pfizer) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Medical advancements don’t just spring up—they happen by building on decades of previous discoveries. Today, one of these advancements might be on the verge of another breakthrough. But what had to happen first for it to exist? In this episode, co-hosts Dr. Raven Baxter and Dr. Ronald Gamble explore how a vaccine candidate for a deadly, once-mysterious bacterial disease came to be. The story takes them from one doctor’s groundbreaking connection in the 70s, all the way to a real lab where vaccines are being developed today. Featured Guests: – Carol Baker, Pediatric Infectious Disease Specialist – Isis Kanevsky, Senior Director, Vaccines, Pfizer – Ksenia Krylova, Senior Director, Vaccines, Pfizer Dive into the episode here: 02:54 - Getting into the problem 05:11 - The basics of immunity and vaccine science 09:32 - What is a conjugate vaccine? 14:44 - Group B Strep: A case study 22:23 - Talking to a GBS pioneer 31:40 - A trip to the lab 43:08 - What's next, and closing thoughts Season 5 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter and Dr. Ronald Gamble. It’s produced by Acast Creative Studios. Check out our social media platforms to take a deeper look into the labs and stories we discuss during the episodes: Instagram (@pfizerinc), TikTok (@pfizer) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Science Will Win is back for a new season, with new hosts and a new format. Now, science educators Dr. Raven Baxter a molecular biologist otherwise known as Raven, the Science Maven, and Dr. Ronald Gamble, a theoretical astrophysicist at NASA, are teaming up to explore four exciting medical technologies. These technologies are right on the cusp of a potentially groundbreaking moment, either unlocking our ability to tackle new diseases or allowing us to tackle old ones in ways we never could before. This journey takes our hosts through discussions with cutting edge researchers, stories of medical mysteries solved, and tours of real labs that are used every day in the quest to create new medicines. Tune in to the latest four-part season, coming soon! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Over the last five years, the healthcare industry has witnessed an explosive surge in digital health services, revolutionizing the way we access medical care. Patients today are taking charge of their health journey by using different digital tools to stay on top of their preventative screenings, implement dietary and lifestyle changes, access mental health resources, and so much more. In this conversation, patient advocates and industry leaders from Noom, Thrive, and Pfizer, dive into the potential power of artificial intelligence and the anticipated transformation in personalized health plans. They share real-world examples that highlight how digital technologies are helping patients feel empowered and shape the future of healthcare.  Through this conversation you heard Lidia Fonseca reference Health Answers by Pfizer. In February 2025, the Pfizer team launched this new platform, powered by generative AI that provides clear, relevant answers to your health & wellness questions and helps you take action for yourself and your loved ones. To learn more, visit healthanswers.pfizer.com. Moderator: Stephanie Agresta, Managing Director, Ascendancy Events  Featured experts: -Karin Bilich, Head of Content, Noom  -Lidia Fonseca, Chief Digital & Technology Officer, Pfizer  -MT Grant, SVP & GM, Thrive for Health This episode was recorded live in Austin, TX on Monday, March 10, as part of Pfizer’s takeover of the South by Southwest podcasting lounge. Please fill out our short survey so we can get to know our listeners better: pfizer.com/podcastsurvey Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

While cancer deaths in the United States have declined in recent years, some populations are being left behind—facing complicated challenges to accessing the care they need. Intervening at the earliest stages of disease onset is critical to cancer treatment success and to reducing the risk of recurrence. So how do we create a world where all people with cancer are quickly diagnosed and can live better, longer lives as science advances? In this conversation, patient advocates and healthcare leaders from Pfizer, the American Cancer Society, and the Healthcare Businesswomen’s Association, discuss the power of collaboration in the effort to “Outdo Cancer.” Moderator • Tyrone McClain, Senior Director, Public Affairs, Pfizer Speakers • Carmen White, U.S. & Global Oncology Health Equity Lead, Pfizer • Pam Traxel, American Cancer Society, Cancer Action Network • Mary Stutts, CEO, Healthcare Businesswomen's Association (HBA) This episode was recorded live in Austin, TX on Monday, March 10, as part of Pfizer’s takeover of the South by Southwest podcasting lounge. Please fill out our short survey so we can get to know our listeners better: pfizer.com/podcastsurvey Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Podcasting has become essential for communicating breakthroughs in science, offering an accessible and engaging platform to reach diverse audiences. This evolving medium fosters deeper connections by delivering trusted information in accessible and compelling ways. In this conversation, audio makers from Pfizer, Acast, and TED, discuss what it takes to stand out in the science podcast space, insights on strategy, and how they're working to shape the future of health communication. Moderator • Aaron Strout, Former CMO of Real Chemistry and Health Podcaster Speakers • Erica Santiago, Executive/Digital Communications & Podcast Strategy, Pfizer • Veronika Taylor, SVP of Acast’s Creator Network • Shoshana Ungerleider MD, Host and Producer of TED Health Podcast This episode was recorded live in Austin, TX on Monday, March 10, as part of Pfizer’s takeover of the South by Southwest podcasting lounge. Please fill out our short survey so we can get to know our listeners better: pfizer.com/podcastsurvey Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

So far in this season, we’ve explored how innovations throughout history have brought us to where we are now. We talked about how drug discovery changed from a serendipity-based to data-based endeavor. Then, we explored the powerful hardware and smart software required to accommodate big data. Now, the door to the future of AI in drug discovery is open. In our final episode, we’re looking toward the future, to understand where today’s advancements could potentially take us. Featured Guests: –Charlotte Allerton, Head of Preclinical and Translational Sciences at Pfizer –Daniel Ziemek, Vice President of Integrative Biology and Systems Immunology at Pfizer –Enoch Huang, Head of Machine Learning and Computational Sciences at Pfizer –Dr. Raza Ali, group leader at the University of Cambridge Cancer Research UK Institute, pathologist Season 4 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.